Purple Biotech PPBT 深 滬
等待開盤 10-28 09:30:00 美东时间
0.5952
+0.005
+0.88%
華盛通- 最 高0.60
- 今 開0.5966
- 成交量 12.88万股
- 最 低 0.5846
- 昨 收 0.59
- 總市值 537.49万
- 52周最高 13.95
- 市盈率 靜 --
- 換手率 1.43%
- 52周最低 0.5326
- 委 比 -22.96%
- 總股本 903.04万
- 歷史最高 1390.00
- 量 比 0.85
- 振 幅 2.61%
- 歷史最低 0.5326
- 每 手 1
- 風險率 1.09%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Purple Biotech announces receipt of Nasdaq minimum bid price notification
Purple Biotech Ltd (NASDAQ:PPBT) said on Monday it received a notice from Nasdaq that its American Depositary Shares (ADSs) have been below the $1 minimum bid price required for continued listing for ...
10-21 04:08
Purple Biotech Announces Receipt of Nasdaq Minimum Bid Price Notification
Purple Biotech Ltd. received a notice from Nasdaq regarding non-compliance with the minimum bid price requirement of $1.00 per share for 30 consecutive trading days. The company has until April 14, 2026, to regain compliance, and if unsuccessful, may have an additional 180 days to meet requirements. The company will monitor its ADS closing bid price and may consider options such as adjusting the ADS-to-ordinary share ratio to address the issue.
10-20 20:00
Purple Biotech Enters New ATM Agreement with H.C. Wainwright
The latest announcement is out from Purple Biotech ( ($PPBT) ). On September 19...
09-20 05:39
Purple Biotech Secures European Patent for NT219 Combinations
An update from Purple Biotech ( ($PPBT) ) is now available. On September 10, 20...
09-10 20:28
Purple Biotech Receives Intention to Grant a European Patent Covering NT219 Combinations with Immunotherapies or MEK Inhibitors to Overcome Tumor Resistance
Purple Biotech Ltd. announced that the European Patent Office has issued an intention to grant a patent for their application on combining NT219 with immunotherapies and other anti-cancer agents. The patent, if granted, will provide protection for NT219 combinations designed to enhance cancer treatment efficacy, particularly in resistant cancers. NT219 targets IRS1/2 and STAT3, key drivers of drug resistance and tumor immune evasion. The company ...
09-10 12:00
Purple Biotech Announces Closing of Up To $18 Million Public Offering $6 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants
Purple Biotech Ltd. 宣布完成5,999,999股美国存托股票（ADS）的公开发行，总金额约600万美元，并附带可额外筹集1200万美元的短期认股权证。资金将用于癌症治疗候选药物的开发及一般运营。
09-05 20:00
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Bone Biologics (NASDAQ:BBLG) stock moved upwards by 38.2% to $2.86 dur...
09-05 01:05
Purple Biotech Announces Pricing of Up To $18 Million Public Offering
Purple Biotech Ltd. announced a public offering of 5,999,999 ADSs and short-term warrants to purchase up to 11,999,998 ADSs at $1.00 per share, with upfront gross proceeds of $6 million and potential additional $12 million upon warrant exercise. The funds will support oncology therapeutic development and general corporate purposes. The offering is underwritten by H.C. Wainwright & Co. and includes candidates CAPTN-3, IM1240, and CM24 targeting tu...
09-04 13:15
Purple Biotech Announces New Data Supporting the Unique Design of CAPTN-3 Tri-Specific Antibody IM1240 in Collaboration with the Icahn School of Medicine at Mount Sinai
Purple Biotech announced new data on its CAPTN-3 tri-specific antibody IM1240, targeting 5T4, a tumor-associated antigen. IM1240 demonstrated tumor cell death in treatment-resistant head and neck cancer biopsies, with synergistic effects between its NK and T cell engager arms. Analysis of human transcriptomes supports the design, showing NKG2A expression consistently accompanies 5T4 in solid tissues. IM1240 is advancing toward first-in-human clin...
09-04 11:00
Purple Biotech Announced Its Second CAPTN-3 Trispecific Antibody, IM1305, Targeting TROP2 In Development, FDA Investigational New Drug Submission Planned For 2026
IM1305 (capped-CD3xTROP2xNKG2A) contains a masked anti-CD3 arm, as well as an anti-NKG2A arm, and an anti-TROP2 arm. The potent anti-CD3 arm is masked at the periphery with a cleavable cap, designed to be removed
09-03 19:14
